CCNH

Cyclin-H

93,332 patent compounds predicted against CCNH, 64,439 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL786323	0.58	15/20
SCHEMBL517413	0.54	15/20
SCHEMBL558222	0.53	15/20
SCHEMBL558223	0.53	15/20
SCHEMBL786603	0.62	14/20
SCHEMBL559356	0.51	14/20
SCHEMBL559412	0.54	13/20
SCHEMBL559413	0.54	13/20
SCHEMBL785897	0.69	11/20
SCHEMBL786343	0.64	11/20
SCHEMBL785935	0.60	11/20
SCHEMBL84411	0.50	11/20
SCHEMBL785871	0.54	10/20
SCHEMBL517461	0.54	10/20
SCHEMBL785963	0.54	10/20
SCHEMBL558878	0.51	10/20
SCHEMBL786533	0.50	10/20
SCHEMBL268925	0.46	10/20
SCHEMBL269583	0.46	10/20
SCHEMBL786867	0.81	9/20

Germline variants in CCNH on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full CCNH gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to CCNH by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)	PHASE3	COMPLETED
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas	PHASE2	RECRUITING
Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma	PHASE2	COMPLETED
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer	PHASE2	COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer	PHASE2	WITHDRAWN
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)	PHASE1/PHASE2	RECRUITING
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC	PHASE2	ACTIVE_NOT_RECRUITING
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer	PHASE2	RECRUITING
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma	PHASE1/PHASE2	RECRUITING
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6	PHASE2	RECRUITING
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)	PHASE2	COMPLETED
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression	PHASE2	COMPLETED
BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors	PHASE2	WITHDRAWN
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.	PHASE1/PHASE2	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers	PHASE1	COMPLETED
Study of FCN-437c in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors	PHASE1	RECRUITING
Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA	PHASE1	RECRUITING
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma	EARLY_PHASE1	RECRUITING
The Use of Immunohistochemical Staining for the Prediction of Wilms Tumour Progression and Recurrence	nan	UNKNOWN
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy	nan	UNKNOWN
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer	nan	COMPLETED
Prevalence of Dysplasia of the Gastric Cardia	nan	COMPLETED
A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction: EXAMINATION Study	nan	COMPLETED
Study of Tissue and Blood Samples From Patients With Low-Grade Glioma	nan	COMPLETED
Co'Moon for Supporting Breast Cancer Patients on Adjuvant Endocrine Therapy	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CCNH binder may also engage these)

Protein	Name	Similarity
Q9R1A0	—	0.999	Q9R1A0 →
Q4R7U4	—	0.999	Q4R7U4 →
Q61458	—	0.998	Q61458 →
Q3ZBL9	—	0.997	Q3ZBL9 →
Q10D80	—	0.978	Q10D80 →
P51947	—	0.968	P51947 →
P25008	—	0.967	P25008 →
Q16JA2	—	0.962	Q16JA2 →
Q7QB13	—	0.962	Q7QB13 →
Q29AI1	—	0.961	Q29AI1 →
P28749	—	0.961	P28749 →
Q8BM85	—	0.960	Q8BM85 →
Q8TEA7	—	0.959	Q8TEA7 →
Q52QT8	—	0.959	Q52QT8 →
Q5BBA8	—	0.959	Q5BBA8 →
Q1EAW8	—	0.958	Q1EAW8 →
Q5F361	—	0.958	Q5F361 →
D3ZS28	—	0.957	D3ZS28 →
Q4WZT9	—	0.956	Q4WZT9 →
A1C7R6	—	0.955	A1C7R6 →
Q62245	—	0.955	Q62245 →
Q2HJF3	—	0.954	Q2HJF3 →
P29994	—	0.954	P29994 →
Q9C1M4	—	0.954	Q9C1M4 →
SNRNP200	U5 small nuclear ribonucleoprotein 200 kDa helicase	0.954	landscape →
CCNE2	G1/S-specific cyclin-E2	0.954	landscape →
Q9UPW5	—	0.954	Q9UPW5 →
SOS1	Son of sevenless homolog 1	0.953	landscape →
Q6P4T2	—	0.953	Q6P4T2 →
Q6NRC7	—	0.953	Q6NRC7 →